Single-dose Preoperative Partial Breast Radiotherapy for Women 50 and Older with Low-risk Breast Cancer
Led by Amsterdam UMC, location VUmc · Updated on 2026-07-16
100
Participants Needed
7
Research Sites
521 weeks
Total Duration
AI-Summary
What This Trial Is About
This research investigates a treatment approach for low-risk breast cancer in female patients aged 50 and above. The study evaluates the effects of a single-dose preoperative partial breast radiotherapy guided by MRI, aiming to measure the rate of complete tumor disappearance at the time of surgery, which occurs between six and twelve months after radiotherapy. Researchers will also monitor tumor response through MRI scans and blood and tumor tissue markers to predict this outcome.
Patients receive a single dose of radiotherapy targeting the tumor area, with doses of 20Gy to the gross tumor volume and 15Gy to the clinical tumor volume. Surgery to conserve the breast is planned around 12 months after radiotherapy if MRI shows a complete response. If MRI indicates an incomplete response or disease progression, surgery may be moved earlier, around six months or sooner. During the months between radiotherapy and surgery, MRI scans occur every three months to monitor tumor response.
Participants will be assessed regularly using MRI scans and various blood and tissue tests to follow tumor changes and treatment effects. After surgery, patients will be followed for up to 10 years to evaluate cancer outcomes, side effects, cosmetic results, and quality of life. The primary measure is the complete pathological response at 12 months post-radiotherapy, with secondary measures including radiologic response, adverse events, quality of life, cosmetic outcomes, recurrence rates, survival, and biomarkers related to radiotherapy effects.
CONDITIONS
Brief Title
Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients
Research Team
J
Janneke van Roij, MD
D
Desirée van den Bongard, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients eligible for endocrine therapy but not for chemotherapy or HER2-targeted therapy according to guidelines
You will not qualify if you...
Legal incapacity
BRCA1, BRCA2, or CHEK2 gene mutation
Presence of distant metastasis
Previous history of breast cancer or DCIS
Other malignancy within 5 years before breast cancer diagnosis, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin
Collagen synthesis disease
Signs of extensive DCIS component on biopsy or imaging
Invasive lobular carcinoma
Absolute contraindications for MRI
Nodal involvement confirmed by cytology or histology
Indication for (neo-)adjuvant chemotherapy
Non-feasible dosimetric radiotherapy plan
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 1 day
Participants receive a single dose of preoperative partial breast radiotherapy targeting the tumor area.
1 visit (in-person)
Monitoring Period
Duration - Up to 12 months
Participants undergo MRI scans every 3 months to monitor tumor response after radiotherapy until surgery.
MRI every 3 months
Surgery
Duration - 1 day
Participants have breast conserving surgery scheduled based on MRI results, either at 6 or 12 months after radiotherapy, or earlier if disease progresses.
1 visit (in-person)
Follow-up
Duration - Up to 10 years
Participants are followed for up to 10 years after radiotherapy to assess cancer outcomes, side effects, cosmetic results, and quality of life.
Periodic visits for assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Study Comparing 3D-Printed Biodegradable Breast Implants, Traditional Breast-Conserving Surgery, and Silicone Implant Reconstruction for Breast Cancer Patients
Ultrahypofractionated 5-Session Whole Breast Radiotherapy with Boost versus Standard 15-Session Radiotherapy for Breast Cancer Patients with Unfavorable Characteristics
Phase II Study Comparing 5-Day vs. 9-Day Whole Breast Radiotherapy with Boost in Early-stage Breast Cancer
Evaluating 68Ga-FAPI PETCT for Checking Axillary Lymph Node Status After Neoadjuvant Therapy in Women with Breast Cancer
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial-a study protocol.